Skip to content

Integra LifeSciences IART Tissue Reconstruction — Goodwill

Other segment segments

Specialty Surgery
$343.1M

Similar metrics at other companies

Enovis logo
ENOVReconstructive: — Goodwill impairment
$343.4M+316%
Bausch + Lomb logo
BLCOSurgical — Goodwill
$456M+28.5%
Tenet Healthcare logo
THCAmbulatory Care — Goodwill
$8.69B+7.4%
Select Medical Holdings logo
SEMRehabilitation Hospital — Goodwill
$517.6M+4.1%
Vontier logo
VNTRepair Solutions — Goodwill
$15.2M0.0%
Rithm Capital logo
RITMResidential Transitional Lending — Goodwill
$55.73M0.0%

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B-56.8%
Enterprise value$3.12B-26.7%
P/S0.8×-1.1×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's tissue reconstruction — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's tissue reconstruction — goodwill?
Integra LifeSciences (IART) reported tissue reconstruction — goodwill of $270.15M in Q1 2026.
What does tissue reconstruction — goodwill mean?
This reflects the carrying value of goodwill specifically allocated to the Tissue Reconstruction segment following business acquisitions. It represents the premium paid over the fair value of net identifiable assets, serving as a monitor for potential impairment risks within this business unit.